VivoSeq
Hematology

Hematopoietic Stem Cell Mobilization

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Hematopoietic Stem Cell Mobilization is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Unknown status2 · 50%
Completed1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
Unknown status·—·N/A·NCT05510089·62 enrolled
Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
Completed·—·Phase 2·NCT02139280·58 enrolled
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02015013·40 enrolled
Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization
Unknown status·—·N/A·NCT02184897·24 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)